Domestic pharmaceutical companies threw money worth of KRW 33 billion in the sky due to ‘new drug adoption’

Since it is observed that financial damages on each new drug that companies give up on registration of the insurance benefit is approximately KRW 2.2 billion, it is now required for the government to step forward on the issue.

According to the industry concern, an analysis result of the Korean Pharmaceutical Manufacturer Association showed that losses made through giving up on registration of ...